Novartis gains CHMP support for Eylea competitor in wet AMD

EMA's CHMP issued a positive opinion for Novartis’ Beovu brolucizumab in its December roundup of opinions, none of which were negative.

The agency backed an MAA from Novartis AG (NYSE:NVS; SIX:NOVN) for Beovu to treat wet age-related macular degeneration (AMD). FDA approved the single-chain antibody fragment against VEGF for the indication in October...